Medicaid Rebate Ceiling Raised To 125% In Senate Legislation
Executive Summary
Senate Finance Committee's drug pricing bill would also exclude authorized generics from calculation of average manufacturer prices and rebates and authorize installment-type payments for curative gene therapies.
You may also be interested in...
US Pharma Faces First Drug Pricing Fight Of 2021
A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.
Medicaid Rebate Reform: A Sign Of Minimal Drug Pricing Threats Or A Warning Of More To Come?
House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.
Medicaid Value-Based Payment Proposal Stops Short Of ‘Portability’ Solutions
US Congress may need to weigh in on how installment payments would be handled if patients switch from Medicaid to commercial insurance or from one state Medicaid plan to another, congressional staffer suggests.